MetaCap

Celularity (CELU) vs Citius Pharmaceuticals (CTXR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Citius Pharmaceuticals (CTXR) has outperformed Celularity (CELU) over the past year, losing 55.4% versus a loss of 73.5%. Over five years, CTXR leads with a -98.8% price change compared with -99.3% for CELU. Celularity is the larger company by market cap ($15.0 million vs $14.0 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CELU-73.54%CTXR-55.39%
+31%-24%-79%
Nov 21, 20251 yearNov 20, 2026
CELU-99.34%CTXR-98.81%
+83%-12%-108%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CELU versus CTXR key metrics
MetricCELUCTXR
Share price$0.463$0.5085
Market cap$15.02M$13.96M
1-day change-1.05%+2.27%
YTD return-58.29%-34.56%
1-year return-73.54%-55.39%
5-year return-99.31%-98.79%
EPS (TTM)$-1.69$-1.75
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$26.55M—
Revenue growth (YoY)-51.03%—
Net income (latest FY)$-91.72M$-39.74M
Gross margin24.39%—
Operating margin-230.92%—
Net margin-345.45%—
52-week high$2.55$1.54
52-week low$0.42$0.37
Distance from 52-week high-81.84%-66.98%
Analyst consensus—none
Avg. price target upside—+686.63%
Average volume3.95M275.44K
Shares outstanding32.45M27.45M
Employees11523
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CTXR has outperformed CELU by 18.1 percentage points over the past year.

About Celularity

CELU stock →

Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking.

Health Care · Biotechnology: Pharmaceutical Preparations · 115 employees

About Citius Pharmaceuticals

CTXR stock →

Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma.

Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees

CELU vs CTXR FAQ

Which is bigger, Celularity or Citius Pharmaceuticals?

Celularity (CELU) is larger, with a market capitalization of $15.02M compared with $13.96M for Citius Pharmaceuticals (CTXR).

Which stock has performed better over the past year, CELU or CTXR?

CTXR returned -55.39% over the past 12 months, compared with -73.54% for CELU (price return, excluding dividends). Past performance does not predict future results.

Are Celularity and Citius Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons